Skip to main content

Clinical trial CA045-001

A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma

Cancers
Organ Skin
Trial status Trial closed
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor BMS - Bristol Myers Squibb int.
EudraCT Identifier 2018-001423-40
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03635983
Inclusion criteria Stage III or IV, unresecable
Last update